The total number of shares in Elekta as of December 30, 2013, amounts to
382,828,114 divided between 14,250,000 A-shares and 368,578,114 B-shares.
The increase of 1,879 new B-shares is attributable to the conversion of shares
within the framework of the 2012/17 convertible bond.
One A-share entitles the holder to ten votes and one B-share to one vote.
For further information, please contact:
Johan Andersson, Director Investor Relations, Elekta AB.
Tel: +46 702 100 451, email: firstname.lastname@example.org.
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 18.00 CET on December 30, 2013.
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO: EKTAB. Website:
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.